Please ensure Javascript is enabled for purposes of website accessibility

Why CVS Health Lost 13% in the First Half of the Year

By Jeremy Bowman - Jul 8, 2020 at 4:55PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Despite some tailwinds from COVID-19, the drugstore chain doesn't expect earnings growth this year.

What happened

You might think that a healthcare leader like CVS Health (CVS -0.25%) would have been poised to outperform during the COVID-19 pandemic, but that has not been the case so far. Shares of the nation's largest drugstore chain and the parent of health insurer Aetna slipped 13% through the first six months of the year, according to data from S&P Global Market Intelligence, as pandemic-related uncertainty reigned over expectations.

Shares of CVS tracked similarly to the S&P 500 but underperformed the broad-market index for much of the year.

CVS Chart

CVS data by YCharts

So what

CVS stock traded mostly flat through the first weeks of the year as the pharmacy began to roll out its new HealthHUBs, a cornerstone of its strategy, and posted fourth-quarter earnings in February that were better than expectations. The company saw 22.9% revenue growth to $66.9 billion as it got a boost for the last time from the Aetna acquisition, topping estimates at $63.97 billion. Adjusted earnings per share fell from $2.14 to $1.73, in part because of share dilution form the Aetna deal, but that beat expectations at $1.69. Citing "significant progress" made in 2019, CEO Larry Merlo said the company was raising its guidance for 2020, calling for adjusted EPS between $7.04 and $7.17, essentially flat with $7.08 in 2019.

A CVS pharmacist greeting a little girl

Image source: CVS Health.

The stock then plunged in March along with the rest of the market, though CVS also announced that it would hire 50,000 new employees and begin opening up testing sites, showing that there was high demand for its services. At the same time, the company acknowledged headwinds caused in part by lower prescription volumes as Americans stayed home and put off doctor visits.

By the time CVS' first-quarter earnings report came around in May, its stock had regained some of those losses, and it again beat estimates with adjusted EPS of $1.91, up from $1.62 a year ago. However, the company did not raise its guidance, which may have disappointed investors.

Now what

Though the pandemic has driven additional retail sales for CVS, and the company has opened more than 1,000 testing sites, the crisis has forced it to suspend its HealthHUB rollout and focus instead on fighting the coronavirus. While the pharmacy chain still faces considerable uncertainty ahead, it should emerge from the pandemic in a competitively strong position. Trading at a P/E around nine, the stock looks cheap.

Jeremy Bowman owns shares of CVS Health. The Motley Fool recommends CVS Health. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

CVS Health Corporation Stock Quote
CVS Health Corporation
$102.00 (-0.25%) $0.26

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/09/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.